Novozymes A/S (OTCMKTS:NVZMY) issued its quarterly earnings data on Wednesday. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.46 by ($0.03), Morningstar.com reports. Novozymes A/S had a net margin of 21.52% and a return on equity of 28.25%.

Novozymes A/S (OTCMKTS NVZMY) traded down $0.35 during trading on Thursday, hitting $50.11. The stock had a trading volume of 1,247 shares, compared to its average volume of 23,287. The stock has a market cap of $13,613.07, a PE ratio of 32.35, a P/E/G ratio of 2.34 and a beta of 0.90. Novozymes A/S has a 12 month low of $37.73 and a 12 month high of $57.84.

Several analysts have issued reports on the stock. Zacks Investment Research downgraded shares of Novozymes A/S from a “buy” rating to a “hold” rating in a research report on Wednesday, December 27th. Jefferies Group reaffirmed a “hold” rating and issued a $54.97 price objective on shares of Novozymes A/S in a research report on Thursday, October 26th.

COPYRIGHT VIOLATION WARNING: “Novozymes A/S (NVZMY) Announces Quarterly Earnings Results” was originally reported by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2018/02/08/novozymes-a-s-nvzmy-announces-quarterly-earnings-results.html.

About Novozymes A/S

Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America.

Earnings History for Novozymes A/S (OTCMKTS:NVZMY)

Receive News & Ratings for Novozymes A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S and related companies with MarketBeat.com's FREE daily email newsletter.